Stay updated on Nivolumab in Type B3 Thymoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Type B3 Thymoma Clinical Trial page.

Latest updates to the Nivolumab in Type B3 Thymoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check46 days agoChange DetectedThe page now indicates that some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. Additionally, the status of a service has been updated to 'Verified 2023-02' by the European Organisation for Research and Treatment of Cancer, while the previous status 'Active, not recruiting' has been removed.SummaryDifference2%
- Check53 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check68 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check75 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.2%
- Check104 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to Nivolumab in Type B3 Thymoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Type B3 Thymoma Clinical Trial page.